Infectious Diseases Cluster (IDCluster)

The biocluster dedicated to combating emerging infectious diseases and antimicrobial resistance

Infectious Diseases Cluster (IDCluster) aims to transform innovative projects led by academic researchers, start-ups, SMEs, and large companies into industrial solutions to better prevent and combat the threat of Emerging Infectious Diseases (EID) and Antimicrobial Resistance (AMR) in both pre-pandemic and pandemic periods.

Our missions

Connect

the ecosystem involved in combating emerging infectious diseases (EID) and antimicrobial resistance (AMR) to create synergies between academic, university hospital, institutional, and private actors (large companies, SMEs/VSEs, and start-ups) and foster the emergence of innovative projects

Accelerate

the development of collaborative R&D projects in pre-industrial innovations, through various support programs, then facilitate their transition to the industrial level

Implement

the deployment and use of epidemiological surveillance solutions, vaccination products, diagnostics, and treatments to provide rapid responses in both pre-pandemic and pandemic periods

Corporate presentation

Our convictions

Working together to better prepare France for pandemic risks

No organization can single-handedly respond to the challenges posed by emerging infectious threats and antimicrobial resistance.

By combining the strengths of public health authorities, academic research, and economic players in R&D, we can make faster and more effective progress.

Infectious Diseases Cluster aims to be a collaborative, open, and cross-disciplinary organization working toward this common goal.

Capitalizing on collective experience and momentum

France has solid experience in the field of infectious diseases, enriched by the lessons learned from the COVID-19 crisis. Since then, many academic and industrial players and facilitators—such as competitiveness clusters—have mobilized to strengthen coordination and innovation in this field.

Infectious Diseases Cluster builds on these achievements and on innovations already underway to accelerate the collective transformation of these initiatives into concrete solutions.

Promoting talent and confidence in science

France boasts an exceptional wealth of passionate researchers, innovators, laboratories, and companies determined to protect the population.

Our country is brimming with talent and conviction in the fields of emerging infectious diseases (EID) and antimicrobial resistance (AMR).

Infectious Diseases Cluster is a hive of activity for those who believe in the power of science, research, and innovation to meet the challenges posed by these health risks.

Governance

Founders and Board Members

Inserm ANRS MIE, represented by Yazdan YAZDANPANAH

AP-HP, represented by Milan LAZAREVIC

bioMérieux, represented by Alexandre MÉRIEUX

Ceva Santé Animale, represented by Marc PRIKAZSKY

Hospices Civils de Lyon, represented by Alexandre PACHOT

Institut Pasteur, represented by Christophe D’ENFERT

Lyonbiopôle, represented by Erick LELOUCHE

Sanofi, represented by Paul-Alan DOLLINGER

Université Claude Bernard Lyon 1, represented by Bruno LINA

Université Paris Cité, represented by Odile LAUNAY

Chairman of the Board

Bruno LINA

Operations Team

Christophe JACQUINET

General Manager

Perrine JEANTET

Operations Coordinator

Philippe LEISSNER

Head of Development & Partnerships

Strategic Advisory Committee

François LACOSTE

Chairman of ID Cluster Strategic Advisory Committee Executive

Vice President Public Health, Medical & Scientific Affairs, Institut Mérieux

Paola ARIMONDO

Head of the Epigenetic Chemical Biology Unit, Institut Pasteur

Isabelle FUGIER

Director, Head of R&D French Networks & Initiatives, Sanofi Vaccines

Delphine GUYON-GELLIN

Chief Business Development Officer and Chief Operating Officer, Osivax

Dimitri LAVILETTE

CIRI Director (International Centre for Research in Infectious Diseases)

Xavier LESCURE

Infectious Disease Specialist, AP-HP, Assistance Publique - Hôpitaux de Paris

Jean-François LLITJOS

Vice President, Head of Innovation and Partnerships, bioMérieux

Eric QUÉMÉNEUR

Director of the France Vaccines Program, INSERM

Hervé RAOUL

Deputy Director, ANRS Emerging Infectious Diseases

Gilles SALVAT

Laboratory Director and Director of Animal Health and Welfare, ANSES, French Agency for Food, Environmental and Occupational Health & Safety

Édouard TIMSIT

Global Innovation Livestock Health Director, Ceva Animal Health

France 2030 Strategy

The 2030 Health Innovation Plan: a strategy to become Europe’s leading innovative and sovereign nation in healthcare

€7.5 billion in investments to strengthen:

Biomedical research excellence.
The transformation of scientific discoveries into concrete medical innovations.
The competitiveness of the French healthcare industry

€300 million dedicated to five world-class bioclusters in France.

A biocluster is an innovation ecosystem bringing together laboratories, research centers, healthcare centers, and companies working in the healthcare sector, which collaborate on a breakthrough innovation issue.

ID Cluster is one of the five bioclusters supported by France 2030.

Led by the General Secretariat for Investment, France 2030 has two ambitions: to transform key sectors of our economy in a sustainable way through technological innovation, and to position France as a leader in tomorrow’s world.

To learn more

President of the Republic’s speech announcing the creation of 5 bioclusters

2030 health innovation strategy

France 2030 Financing